Nanobodies developed to image COVID-19 Spike protein
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
List view / Grid view
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
The visualisation platform is being used to analyse how the SARS-CoV-2 virus causing COVID-19 is evolving and could be used to inform drug design.
Researchers comparing the effects of SARS-CoV-2, SARS-CoV and MERS-CoV in cynomolgus macaques suggest they could be an effective animal model for testing COVID-19 therapeutics.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
After screening 300 antibodies, Celltrion has identified the 14 most powerful that could potentially combat the COVID-19 coronavirus.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
Chinese researchers who determined the crystal structure of the COVID-19 protease Mpro used this information to screen over 10,000 compounds to combat the coronavirus.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
Sequencing almost 60,000 cells, researchers have found that certain cilia progenitor cells have gene transcripts for ACE2 and co-factor TMPRSS2, enabling COVID-19 infection.
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.